Ming Li

Biochar (BC) is a carbon-rich porous material, which can increase soil organic matter content. The impacts of BC on soil properties have been widely investigated, however, the impacts of BC on bioaccumulation of pesticides in crops and the toxic effects to crops are less studied. Herein, batch experiments were carried out, the BC (0.02, 0.2, 2%) and atrazine (ATR)/acetochlor (ACE) were applied individually or in combination into soil to separately cultivate soybean/maize in greenhouse. On day 45, soybean and maize were sampled to measure ATR or ACE concentration: ATR concentration in soybean of 2%BC + ATR treatment group reached 24.55 ng/g, which was significantly (p < 0.05) lower than that of ATR-only treatment group (26.04 ng/g); meanwhile, ACE concentration in maize of 2%BC + ACE treatment group reached 4.87 ng/g, which was significantly (p < 0.05) lower than that of ACE-only treatment group (5.27 ng/g). Results showed that BC in soil slightly reduced ATR/ACE entering soybean/maize plants, which was due to that the existence of BC accelerated the degradation of ATR and ACE. In addition, the changes in MDA content, root electrolytic leakage, total chlorophyll, and soluble sugar of soybean in 2%BC + ATR treatment group were 0.93-fold, 0.81-fold, 1.11-fold, and 1.1-fold of ATR-only treatment group; the changes in MDA content, root electrolytic leakage, total chlorophyll, and soluble sugar of maize in 2%BC + ACE treatment group were 0.88-fold, 0.95-fold, 1.16-fold, and 1.1-fold of ACE-only treatment group, indicating that BC mitigated pesticide-induced stress. This study provides novel insight of utilizing BC to deal with organic pollutants in soil.

BiVO ₄ /ZnIn ₂ S ₄ was synthesized via a hydrothermal method, which enabled rapid decomposing Congo red under visible light, providing a feasible strategy for fabricating high-efficiency photocatalysts in water treatment.

Intraoperative localization of ground-glass nodules (GGNs) is challenging. This study evaluates a CT-guided protocol that innovatively combines a glucose solution test with tissue adhesive marking to enhance safety and efficacy. The standardized procedure involves preoperative thin-slice CT (≤1 mm) with a 5 × 5 cm grid for planning, followed by percutaneous puncture to a shallow (5 mm) subpleural depth. A key safety innovation is the injection of 0.3 mL of 5% glucose solution to confirm extra-bronchial needle position via cough reflex testing before depositing 0.3 mL of 2-octyl cyanoacrylate to create a palpable marker. This protocol not only achieves precise localization of pulmonary nodules but also significantly reduces the incidence of pneumothorax by minimizing the number of required puncture attempts. The method is readily reproducible and integrates seamlessly into standard preoperative workflows. This approach establishes a safer, non-radioactive alternative for GGN localization, with its core innovations -- the glucose confirmation step and shallow subpleural injection -- serving as key mechanisms for complication prevention.

Intraoperative localization of ground-glass nodules (GGNs) is challenging. This study evaluates a CT-guided protocol that innovatively combines a glucose solution test with tissue adhesive marking to enhance safety and efficacy. The standardized procedure involves preoperative thin-slice CT (≤1 mm) with a 5 × 5 cm grid for planning, followed by percutaneous puncture to a shallow (5 mm) subpleural depth. A key safety innovation is the injection of 0.3 mL of 5% glucose solution to confirm extra-bronchial needle position via cough reflex testing before depositing 0.3 mL of 2-octyl cyanoacrylate to create a palpable marker. This protocol not only achieves precise localization of pulmonary nodules but also significantly reduces the incidence of pneumothorax by minimizing the number of required puncture attempts. The method is readily reproducible and integrates seamlessly into standard preoperative workflows. This approach establishes a safer, non-radioactive alternative for GGN localization, with its core innovations -- the glucose confirmation step and shallow subpleural injection -- serving as key mechanisms for complication prevention.

Heat ablation techniques, such as microwave and radiofrequency ablation, are established interventions for hepatocellular carcinoma (HCC). However, incomplete ablation often leads to angiogenesis‐driven metastasis and recurrence, undermining long‐term treatment efficacy. The molecular mechanisms facilitating post‐ablation angiogenesis remain poorly understood. In this study, we identified a marked upregulation of SERPINE1 following sublethal heat treatment, which was corroborated in both rabbit models and human HCC cell lines. Further investigation revealed that SERPINE1 promotes angiogenesis, at least in part, through vascular endothelial growth factor A (VEGFA) activation after sublethal heat exposure. We further delineated that METTL3 and IGF2BP1 regulate SERPINE1 expression via an N6‐methyladenosine (m6A)‐dependent pathway. The proangiogenic role of SERPINE1 was substantiated using patient‐derived HCC organoids and in vivo models, where the small‐molecule inhibitor PAI‐039 significantly attenuated sublethal heat ablation‐induced angiogenesis and tumor proliferation. Our findings illuminate the METTL3/IGF2BP1/SERPINE1/VEGFA axis as a novel therapeutic target for improving HCC heat ablation outcomes. Therapeutically, PAI‐039 emerges as a potent adjunctive agent that could synergistically enhance the efficacy of thermal ablation in HCC management.

Objective: To evaluate the effect of postoperative adjuvant immune checkpoint inhibitor (ICI) therapy on survival outcomes in resectable non‐small cell lung cancer (NSCLC) patients who received neoadjuvant chemoimmunotherapy. Methods: A retrospective cohort study was conducted at Zhongshan Hospital, Fudan University, from January 2019 to June 2024, including resectable NSCLC patients treated with neoadjuvant chemotherapy combined with ICIs. Pathological responses were assessed, and event‐free survival (EFS) and overall survival (OS) were compared between patients who received postoperative adjuvant ICI therapy and those who did not. Results: Among the 186 patients included, 106 received adjuvant ICI therapy, while 80 did not. No significant differences in EFS or OS were observed between the two groups in patients who achieved pathological complete response (pCR) or major pathological response (MPR) (EFS: p = 0.282, OS: p = 0.330). In contrast, patients who did not achieve pCR or MPR experienced a significant improvement in EFS with adjuvant ICI therapy ( p = 0.004). An AI‐based decision tree model developed to predict the need for postoperative adjuvant immunotherapy demonstrated strong performance, with an accuracy of 85% and an area under the curve (AUC) of 0.82. Key predictors identified by the model included pathological response, age, clinical stage, and PD‐L1 expression. Conclusions: Postoperative adjuvant ICI therapy significantly improves EFS in resectable NSCLC patients, especially in those without pCR or MPR. However, its effect on OS remains uncertain. These findings highlight the importance of personalized treatment strategies, with adjuvant ICI offering greater benefits for patients with incomplete pathological responses.

Gating strategy and knockdown efficiency.

RETSAT links retinoid metabolism to ferroptosis.

RETSAT is a pro-ferroptosis gene.

RETSAT mediates ferroptosis by activating the retinoic acid receptor pathway.